- Aug 14, 2018
- 638
- 346
- 63
Of all the health questions around anabolic steroid use, the cardiovascular one has the strongest research behind it — and it's the one gym culture discusses least honestly. This is an education thread: no judgment, no instructions, just what the long-term studies have actually found, because anyone weighing these decisions deserves the real numbers rather than either scare stories or bro-science reassurance.
The most cited study is Baggish and colleagues' 2017 paper in Circulation, which compared long-term anabolic steroid users with non-using lifters using cardiac imaging. The users showed measurably worse heart function on both sides of the heart: the left ventricle pumped less efficiently, relaxed less well, and carried more plaque in the coronary arteries — and greater lifetime exposure tracked with more plaque. Importantly, some of the pumping dysfunction appeared to improve in users who had stopped, while the plaque, once laid down, is the kind of change that doesn't simply reverse. Work from Harrison Pope, Gen Kanayama and colleagues following user cohorts has added consistent findings: adverse lipid shifts (HDL cholesterol is often dramatically suppressed during use), raised blood pressure, and thickening of the heart muscle wall — a remodelling pattern cardiologists associate with higher long-term risk.
There are also registry studies from Scandinavia linking anabolic steroid use to higher rates of cardiovascular events and earlier mortality compared with matched controls. These designs can't prove causation the way a randomized trial would — and such a trial will never ethically exist for long-term high-dose use — but the consistency across imaging studies, cohort studies, and known mechanisms (lipids, blood pressure, direct effects on heart muscle cells and clotting) is why cardiology reviews treat the risk as real rather than speculative.
What does the research say reduces harm, in general educational terms? Duration and total exposure matter in the data — the worst cardiac findings cluster in the longest-running users — and the studies consistently associate worse profiles with the absence of medical monitoring. Blood pressure and lipids are measurable, and in the clinical literature they're the markers physicians watch in anyone exposed to androgens, including patients on prescribed testosterone therapy, where monitoring is standard practice. The gap between "prescribed and monitored" and "unmonitored" is a recurring theme in the research.
Questions about this stuff can be asked here anonymously — that's a deliberate feature of this community. Nobody should have to choose between embarrassment and information.
A note on what the research can't tell us, because honesty runs both directions: there are no long-term randomized trials, user studies rely partly on self-reported histories, and people who use anabolics differ from non-users in other ways that studies try, imperfectly, to adjust for. Dose-response also matters and the studies suggest a gradient rather than a cliff — the findings in short-term, lower-exposure users are less alarming than in the decade-plus group. But uncertainty about the exact size of a risk is not the same as evidence the risk is zero, and the direction of every major line of evidence points the same way.
For those who've read the Baggish study or followed this literature: what surprised you most? And do you think the heart research gets the attention it deserves compared to the cosmetic side effects everyone talks about?
The most cited study is Baggish and colleagues' 2017 paper in Circulation, which compared long-term anabolic steroid users with non-using lifters using cardiac imaging. The users showed measurably worse heart function on both sides of the heart: the left ventricle pumped less efficiently, relaxed less well, and carried more plaque in the coronary arteries — and greater lifetime exposure tracked with more plaque. Importantly, some of the pumping dysfunction appeared to improve in users who had stopped, while the plaque, once laid down, is the kind of change that doesn't simply reverse. Work from Harrison Pope, Gen Kanayama and colleagues following user cohorts has added consistent findings: adverse lipid shifts (HDL cholesterol is often dramatically suppressed during use), raised blood pressure, and thickening of the heart muscle wall — a remodelling pattern cardiologists associate with higher long-term risk.
There are also registry studies from Scandinavia linking anabolic steroid use to higher rates of cardiovascular events and earlier mortality compared with matched controls. These designs can't prove causation the way a randomized trial would — and such a trial will never ethically exist for long-term high-dose use — but the consistency across imaging studies, cohort studies, and known mechanisms (lipids, blood pressure, direct effects on heart muscle cells and clotting) is why cardiology reviews treat the risk as real rather than speculative.
What does the research say reduces harm, in general educational terms? Duration and total exposure matter in the data — the worst cardiac findings cluster in the longest-running users — and the studies consistently associate worse profiles with the absence of medical monitoring. Blood pressure and lipids are measurable, and in the clinical literature they're the markers physicians watch in anyone exposed to androgens, including patients on prescribed testosterone therapy, where monitoring is standard practice. The gap between "prescribed and monitored" and "unmonitored" is a recurring theme in the research.
Questions about this stuff can be asked here anonymously — that's a deliberate feature of this community. Nobody should have to choose between embarrassment and information.
A note on what the research can't tell us, because honesty runs both directions: there are no long-term randomized trials, user studies rely partly on self-reported histories, and people who use anabolics differ from non-users in other ways that studies try, imperfectly, to adjust for. Dose-response also matters and the studies suggest a gradient rather than a cliff — the findings in short-term, lower-exposure users are less alarming than in the decade-plus group. But uncertainty about the exact size of a risk is not the same as evidence the risk is zero, and the direction of every major line of evidence points the same way.
For those who've read the Baggish study or followed this literature: what surprised you most? And do you think the heart research gets the attention it deserves compared to the cosmetic side effects everyone talks about?